Fall Out from Myriad – New Gene Patent Testing and Prices Are Starting to Fall

Quest is out with news that it will sell a BRACA gene patent test for 40% less than Myriad’s BRACA gene patent test. Meanwhile, Mryiad and others remain in litigation, with Quest having sued Myriad just prior to announcing the new test.

#Cancer